Skip to main content

Table 1 Analysis of confounding patient-related factors

From: Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

Patient characteristic, n (%)

NAVIGATOR

Study 1002

n = 19

P value

All doses

n = 56

300/400 mg

n = 38

NAVIGATOR

All doses vs Study 1002

NAVIGATOR

300/400 mg vs Study 1002

Sex

0.601

0.844

 Male

39 (70)

25 (66)

12 (63)

  

 Female

17 (30)

13 (34)

7 (37)

  

Agea

0.046*

0.088

  < 60 years

18 (32)

13 (34)

11 (58)

  

  ≥ 60 years

38 (68)

25 (66)

8 (42)

  

Race

0.101

0.042*

 White

39 (78)

25 (71)

18 (95)

  

 Non-white

11 (22)

10 (29)

1 (5)

  

 Missing

6

3

0

  

Anatomical siteb

0.757

0.823

 Gastric (stomach)

46 (82)

29 (76)

15 (79)

  

 Small bowel or rectal

   (any other organ)

10 (18)

9 (24)

4 (21)

  

Metastatic diseasea

0.745

0.611

 No

2 (4)

1 (3)

1 (5)

  

 Yes

54 (96)

37 (97)

18 (95)

  

ECOG Performance Statusa

0.445

0.400

 0

21 (38)

13 (34)

1 (100)

  

 1

32 (57)

23 (61)

0

  

  ≥ 2

3 (5)

2 (5)

0

  

 Missing

0

0

18

  

Duration of diseasec

0.386

0.340

  < 3 years

32 (57)

21 (55)

13 (68)

  

  ≥ 3 years

24 (43)

17 (45)

6 (32)

  

Number of TKI treatment linesd

0.124

0.040*

 1

11 (20)

5 (13)

3 (16)

  

 2

23 (41)

20 (53)

3 (16)

  

 3

9 (16)

6 (16)

4 (21)

  

  ≥ 4

13 (23)

7 (18)

9 (47)

  
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor
  2. Not all available baseline and demographic characteristics could be used due to differences in the timing of the measure (i.e., screening in NAVIGATOR vs diagnosis in Study 1002)
  3. aEstimated at the start of reference treatment
  4. bRecorded at the primary diagnosis
  5. cEstimated from the date of diagnosis to the date of start of reference treatment
  6. dThe number of lines of TKIs was counted from the first TKI for treatment of unresectable/metastatic disease including avapritinib for NAVIGATOR population
  7. *P value statistically significant (≤ 0.05); comparison between NAVIGATOR population vs Study 1002 population
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us